Kyowa Hakko Kirin Ends Mogamulizumab License Agreement With Amgen
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin will terminate its licensing agreement with Amgen regarding the antibody drug mogamulizumab (Poteligeo), the company announced on April 17.